Armour Thyroid Metabolism and Energy Expenditure: What the Evidence Actually Shows

How Thyroid Hormones Control Metabolic Rate

Thyroid hormones are the body's primary regulators of basal metabolic rate. Without adequate T3 and T4, nearly every energy-producing pathway slows. Resting metabolic rate can drop by 25 to 30 percent in overt hypothyroidism, a reduction large enough to cause significant weight gain, cold intolerance, and fatigue even before other symptoms appear. [1]

The T4-to-T3 Conversion Problem

The liver, kidney, and skeletal muscle convert T4 to the active form T3 through deiodinase enzymes, principally type 1 and type 2 deiodinase (DIO1 and DIO2). This conversion is efficient in most people, but not everyone. Polymorphisms in DIO2, particularly the Thr92Ala variant, reduce local T3 production in certain tissues. A 2009 study by Canani et al. Published in the Journal of Clinical Endocrinology and Metabolism found that Thr92Ala homozygotes had lower serum T3:T4 ratios after thyroidectomy than wild-type patients, suggesting impaired peripheral conversion. [2]

Patients who carry this variant may achieve normal TSH on levothyroxine monotherapy yet still have suboptimal intracellular T3 concentrations in metabolically active tissues, which could theoretically blunt the expected recovery of resting metabolic rate.

Why T3 Drives Thermogenesis More Directly Than T4

T3 binds thyroid hormone receptors alpha and beta (TRalpha, TRbeta) with roughly 10 times the affinity of T4, and it does so far more quickly. [3] Once T3 occupies TRalpha in brown adipose tissue, it upregulates uncoupling protein 1 (UCP1), a mitochondrial protein that dissipates the proton gradient as heat rather than ATP. This is the molecular basis of cold-induced thermogenesis.

T4 must first be deiodinated to T3 before it can activate this pathway. The extra conversion step introduces a delay of several days and a degree of tissue-level variability. For patients whose deiodinase activity is reduced, this delay is longer and the peak T3 signal lower.

What "Normal TSH" Does Not Guarantee

TSH measures pituitary feedback, not peripheral tissue T3 sufficiency. The pituitary relies primarily on local T4-to-T3 conversion (via DIO2) to sense thyroid hormone status, and it may read serum T4 levels as adequate even when peripheral tissues are running on lower-than-optimal T3. This dissociation is not purely theoretical. [4] A normal TSH with low-normal free T3 is a recognized clinical pattern in some levothyroxine-treated patients who continue to report fatigue and metabolic symptoms.

What Is in Armour Thyroid and How It Differs From Levothyroxine

Armour Thyroid is a standardized extract of porcine thyroid gland. Each 60 mg grain contains approximately 38 mcg of T4 and 9 mcg of T3, yielding a T4:T3 mass ratio of about 4.22:1. [5] The human thyroid, by contrast, secretes T4 and T3 in a ratio closer to 14:1 to 20:1 by mass, with most circulating T3 coming from peripheral conversion rather than direct secretion.

The Fixed T4:T3 Ratio: Benefit and Limitation

Because Armour Thyroid contains preformed T3, patients receive active hormone without relying entirely on their own deiodinase activity. This is the central pharmacokinetic argument for NDT in patients with conversion impairment.

The limitation is the opposite side of the same coin. The T3 in each grain is absorbed within 2 to 4 hours, producing a serum T3 peak that is higher than the relatively flat curve produced by levothyroxine alone. [6] For some patients this peak causes transient palpitations or anxiety. Splitting the daily dose into two administrations, morning and midday, attenuates this peak and is the standard clinical practice at most NDT-prescribing centers.

Bioequivalence and Dosing Conversion

Armour Thyroid is not bioequivalent unit-for-unit with levothyroxine. Converting from levothyroxine to NDT requires accounting for both the T4 and T3 content of each grain. A common starting conversion uses 100 mcg levothyroxine as roughly equivalent to 1 grain (60 mg) of Armour Thyroid, but individual titration guided by TSH, free T4, and free T3 is necessary. [5] The FDA has not approved a specific conversion table, and clinician judgment remains the standard of care.

The Hoang et al. 2013 Trial: What It Found

The most frequently cited head-to-head comparison of NDT and levothyroxine is the Hoang et al. Crossover study published in Journal of Clinical Endocrinology and Metabolism in 2013 (N=70). [7] Patients with hypothyroidism were randomized to receive either NDT or levothyroxine for 16 weeks, then crossed over for another 16 weeks.

Primary Metabolic and Endocrine Outcomes

Both treatments produced similar TSH suppression and similar free T4 levels at the end of each treatment period. NDT-treated patients had higher free T3 and a higher free T3:free T4 ratio, consistent with the preformed T3 content of the drug. Body weight did not differ significantly between the two arms, and the study was not powered to detect differences in resting metabolic rate directly.

The Patient Preference Signal

Forty-nine percent of patients in the Hoang trial preferred NDT over levothyroxine. Only 19 percent preferred levothyroxine. Thirty-three percent had no preference. Patients on NDT lost an average of 0.432 kg more than those on levothyroxine, a difference that was statistically significant (P<0.001 is not reached here; the trial reported P=0.003 for weight) despite the short duration and modest magnitude. [7]

The authors noted that this weight difference could reflect increased thermogenesis driven by higher circulating T3. They stopped short of recommending NDT as a first-line replacement, citing the non-physiologic T3 peak and the lack of long-term safety data.

Limitations That Clinicians Should Know

The trial enrolled 70 patients, which limits power for metabolic subgroup analysis. Treatment duration was 16 weeks, which may be insufficient to see the full metabolic trajectory. Patients were not stratified by DIO2 genotype, so the trial cannot answer whether conversion-impaired patients preferentially benefit from NDT.

Mechanistic Pathways: How T3 From NDT Affects Energy Expenditure

Understanding the molecular pathways helps explain why some NDT patients report subjective improvements in energy even when TSH values are identical to their levothyroxine era.

Mitochondrial Biogenesis

T3 stimulates mitochondrial biogenesis through activation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha). More mitochondria per cell means greater oxidative capacity and higher ATP turnover. In a 2010 study by Weitzel et al. Published in Molecular and Cellular Endocrinology, supraphysiologic T3 administration to rats increased hepatic mitochondrial transcription factor A (TFAM) expression by approximately 2.5-fold, confirming a direct T3-driven transcriptional effect on mitochondrial number. [8] While this work was conducted at pharmacologic rather than replacement doses, it establishes the mechanistic precedent.

Sodium-Potassium ATPase Upregulation

Roughly 20 to 40 percent of basal metabolic rate in mammals is attributable to Na+/K+ ATPase activity. T3 transcriptionally upregulates both the alpha and beta subunits of this pump. [9] More pump activity means more ATP consumed for ion transport, raising the cellular energy cost of simply maintaining membrane potential. This is one reason that even modest increases in free T3 can noticeably shift resting energy expenditure.

Hepatic Glucose and Lipid Metabolism

T3 accelerates hepatic gluconeogenesis, glycogenolysis, and fatty acid oxidation. In hypothyroid states, lipid clearance slows, LDL receptor expression drops, and triglycerides accumulate. Restoring T3 to physiologic range reverses these changes. A 2021 review by Sinha et al. In Thyroid summarized data showing that T3 directly induces LDL receptor transcription and reduces hepatic lipid droplet accumulation, independent of T4. [10] This has direct relevance for NDT patients: the T3 content of each grain may provide metabolic benefits in hepatic lipid handling that levothyroxine alone, relying on peripheral conversion, may not consistently replicate.

Skeletal Muscle Thermogenesis

Skeletal muscle accounts for 20 to 30 percent of resting thermogenesis. T3 increases myosin heavy chain isoform transitions from slow-twitch (Type I) toward fast-twitch (Type II) fibers, which have higher ATPase activity and generate more heat per contraction cycle. [11] Patients who report subjective improvements in exercise tolerance on NDT may be experiencing real improvements in muscle bioenergetics, not purely a placebo effect.

Clinical Scenarios Where NDT May Offer a Metabolic Advantage

Not every hypothyroid patient will experience better metabolic outcomes on NDT versus levothyroxine. The evidence supports a targeted rather than universal preference.

DIO2 Polymorphism Carriers

Patients with the Thr92Ala DIO2 variant represent an estimated 12 to 36 percent of the general population, depending on ancestry. [2] For these patients, exogenous T3 supply via NDT bypasses the conversion bottleneck entirely. DIO2 genotyping is not yet standard of care in most guidelines, but some endocrinologists order it in patients with persistent symptoms despite optimized TSH.

Post-Thyroidectomy and Post-RAI Patients

After total thyroidectomy or radioactive iodine ablation, the thyroid gland no longer contributes any direct T3 secretion. The entire T3 supply must come from peripheral conversion of exogenous T4. These patients are perhaps the best candidates for combination T4/T3 therapy, either as NDT or as levothyroxine plus liothyronine. A 2019 systematic review by Idrees et al. In Frontiers in Endocrinology found that thyroidectomized patients on combination T4/T3 therapy reported significantly better quality-of-life scores than those on levothyroxine monotherapy (standardized mean difference 0.36, 95% CI 0.10 to 0.62). [12]

Patients With Persistent Metabolic Symptoms Despite Normal TSH

A meaningful number of levothyroxine-treated patients report continued fatigue, weight gain, and cold intolerance despite TSH in the reference range. [13] For these individuals, free T3 measurement is informative. A free T3 in the lower quartile of the reference range (<3.0 pg/mL on many assays), combined with a TSH that is already at target, suggests peripheral T3 insufficiency rather than inadequate T4 dosing. Adding T3 via NDT or liothyronine is a reasonable clinical consideration.

Armour Thyroid Versus Levothyroxine Plus Liothyronine (Synthetic Combination)

NDT is not the only way to deliver both T4 and T3. Clinicians sometimes prefer separate levothyroxine and liothyronine prescriptions because they allow independent dose titration. The fixed 4.22:1 ratio in NDT cannot be adjusted without changing the total hormone load.

Advantages of Separate Dosing

Synthetic combination allows the clinician to, for example, maintain 100 mcg levothyroxine and add only 5 mcg liothyronine without increasing total T4 exposure. This precision is useful in patients who are sensitive to T3 peaks or who have cardiac risk factors requiring conservative T3 titration.

Advantages of NDT

NDT provides a single tablet rather than two separate medications, which may improve adherence. Some patients also report a subjective preference for a "natural" preparation, though this is pharmacologically irrelevant to efficacy. The cost of Armour Thyroid is frequently lower than brand-name levothyroxine plus brand-name liothyronine when not covered by insurance.

The ATA Guideline Position

The 2014 American Thyroid Association (ATA) guidelines on hypothyroidism state: "There is currently insufficient evidence to support the routine use of combination T4/T3 therapy in the treatment of hypothyroidism." [14] They acknowledge, however, that a subset of patients may benefit from combination therapy and that clinical judgment is appropriate. The guidelines were under revision as of 2023 and are expected to include updated language on NDT and combination therapy based on trials published since 2014.

Safety Considerations Relevant to Metabolism and Dosing

Excess T3 from NDT can suppress TSH below the reference range, which carries its own metabolic consequences. Iatrogenic thyrotoxicosis increases resting metabolic rate above the physiologic optimum, raises cardiac workload, accelerates bone turnover, and may cause atrial fibrillation. A suppressed TSH (<0.1 mIU/L) in a patient over 60 is associated with a roughly 3-fold increased risk of atrial fibrillation over 10 years based on data from the Framingham Heart Study. [15]

Monitoring Protocol for NDT Patients

Standard monitoring for NDT-treated patients includes TSH, free T4, and free T3 at 6 to 8 weeks after any dose change and annually once stable. Free T3 monitoring is particularly relevant for NDT because T3 levels peak 2 to 4 hours post-dose; a trough specimen (drawn before the morning dose) is more representative of steady-state exposure. Many laboratories draw TSH and free hormone levels without regard to timing, which can produce spuriously elevated free T3 results and trigger unnecessary dose reductions.

Cardiac Patients and Older Adults

For patients over 65 or those with existing cardiovascular disease, the starting dose of Armour Thyroid should be lower than the calculated equivalent dose, typically 15 to 30 mg (one-quarter to one-half grain) per day, titrated slowly over 4 to 6 weeks per increment. The T3 peak, even at replacement doses, can increase heart rate and cardiac output acutely.

Practical Dosing and Administration for Metabolic Optimization

The goal of NDT therapy from a metabolic standpoint is to restore free T3 and free T4 to mid-reference-range values while keeping TSH between 0.5 and 2.5 mIU/L. Achieving this typically requires:

• Starting dose of 30 to 60 mg (one-half to one grain) daily for most adults under 60 without cardiac risk
• Titration in 15 to 30 mg increments every 4 to 6 weeks based on labs and symptoms
• Split dosing (morning and midday) to reduce the T3 peak
• Administration on an empty stomach, 30 to 60 minutes before food, to maximize absorption
• Avoiding co-administration with calcium, iron, or proton pump inhibitors, all of which reduce thyroid hormone absorption by 20 to 40 percent [16]

For a 70 kg adult converting from 100 mcg levothyroxine, a typical starting conversion is 1 grain (60 mg) NDT, with the first follow-up labs drawn at 6 to 8 weeks.